1. Anti-infection
  2. Influenza Virus

Pimodivir (Synonyms: VX-787)

Cat. No.: HY-12353A Purity: 99.04%
Handling Instructions

Pimodivir is an orally bioavailable inhibitor of influenza A virus polymerases through interaction with the viral PB2 subunit.

For research use only. We do not sell to patients.
Pimodivir Chemical Structure

Pimodivir Chemical Structure

CAS No. : 1629869-44-8

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 127 In-stock
2 mg USD 108 In-stock
5 mg USD 144 In-stock
10 mg USD 228 In-stock
25 mg USD 420 In-stock
50 mg USD 648 In-stock
100 mg USD 1128 In-stock
200 mg USD 1968 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Pimodivir is an orally bioavailable inhibitor of influenza A virus polymerases through interaction with the viral PB2 subunit.

In Vitro

Pimodivir rescues macrophages from virus-mediated death at non-cytotoxic concentrations 24 hpi. The EC50 value for Pimodivir are 8 and 12 nM for A(H1N1) and A(H3N2) strains, respectively, whereas the CC50 values are >1 μM, giving selectivity indexes (SI) > 125 and > 83 for A(H1N1) and A(H3N2) strains, respectively. Pimodivir significantly attenuates the transcription of viral M1 RNA in macrophages, which are infected with A(H1N1) or A(H3N2) strains for 8 h. Pimodivir inhibits the transcription of viral but not cellular genes. Pimodivir allows some activation of IAV-mediated expression of several cellular genes, which are involved in tryptophan and nucleotide metabolism. Pimodivir possesses excellent anti-IAV but not immuno/metabolo-modulating effect[2]. Pimodivir is very potent against influenza A strains, including pandemic 2009 H1N1 and avian H5N1[3]. Pimodivir shows potent activity against all influenza A virus strains tested, with an EC50 range of 0.13 to 3.2 nM. Pimodivir-selected PB2 variant viruses maintain susceptibility to neuraminidase inhibitors in vitro[4].

In Vivo

Pimodivir (2, 6, and 20 mg/kg/day, p.o.) and oseltamivir (20 mg/kg/day) completely prevent death in the H1N1pdm virus infection in mice. Pimodivir (20 mg/kg/day) is more effective than oseltamivir (20 mg/kg/day) in improving body weight and reducing the severity of lung infection[1]. Moreover, Pimodivir shows 100% survival in a +48 h delay to treatment mouse influenza model at 10, 3 and 1 mpk (BID × 10 days) whereas the SOC, oseltamivir, provide no survival benefit in this model at 10 mpk[3]. Pimodivir (1, 3, or 10 mg/kg, bid) provided complete survival, with a dose-dependent reduction in BW loss of the mice[4].

Clinical Trial
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 2.5038 mL 12.5191 mL 25.0382 mL
5 mM 0.5008 mL 2.5038 mL 5.0076 mL
10 mM 0.2504 mL 1.2519 mL 2.5038 mL
Please refer to the solubility information to select the appropriate solvent.
Kinase Assay

Virus sensitivity to neuraminidase inhibitors is determined by the chemiluminescent neuraminidase inhibitor assay using an NA-XTD kit. Viruses are diluted in NA-XTD assay buffer (26 mM morpholineethanesulfonic acid, 4 mM CaCl2 [pH 6.0]) such that the signal-to-noise ratio is greater than 40:1. Resistance is defined as determination of a 50% inhibitory concentration greater than 10-fold the mean for the type/subtype. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay

Pimodivir is dissolved in DMSO.

The compound cytotoxicity and efficacy testing is performed in 96-well plates with macrophages at 95% confluence. The compounds are added to the medium, and 30 min later, the cells are infected with virus or non-infected. The cell viability is analyzed with the Cell Titer Glo assay at 24 hpi. The luminescence is read with a PHERAstar FS plate reader. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration

Pimodivir is prepared in 0.5% methylcellulose.

The mice are anesthetized by intraperitoneal injection of ketamine/xylazine (50/5 mg/kg), and the animals are infected intranasally with a 90-μL suspension of influenza virus. The virus challenge is approximately four 50% mouse lethal infectious doses. Treatments are given twice a day (at 12 h intervals) for 10 days starting 2 h before virus challenge. Parameters for assessing the infection are survival, mean day of death, body weight changes, and lung infection parameters (hemorrhage score, weight, and virus titer). Animals are weighed individually every other day through day 21 of the infection. Initially, there are 15 mice per group treated with compound and 25 placebos. Five mice in each group are subsequently sacrificed for determination of lung infection parameters. A larger number of placebos are used than compound-treated mice to achieve greater statistical power, especially if some animals in that group survive the infection. One mouse that dies during the treatment period is presumed to have died from treatment trauma because its death occurs well before other mice die from influenza. It is excluded from the total counts. Animals that die during infection are accounted for in the tabular data. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight







O=C([[email protected]]1C(CC2)CCC2[[email protected]@H]1NC3=NC(C4=CNC5=NC=C(F)C=C54)=NC=C3F)O

Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 12.5 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.04%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: